XIOMARA PORRAS: Open Payments
NPI 1245581883 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,152 in 101 payments from 10 companies in 2025. Trend: 2023 $2,855 · 2024 $2,848 · 2025 $3,152
Food & beverage: $3,042Education: $109
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 23 | $778 |
| Alkermes, Inc. | 18 | $456 |
| Otsuka America Pharmaceutical, Inc. | 12 | $453 |
| Axsome Therapeutics, Inc. | 6 | $395 |
| Teva Pharmaceuticals USA, Inc. | 12 | $346 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $237 |
| Supernus Pharmaceuticals, Inc. | 4 | $207 |
| ABBVIE INC. | 13 | $171 |
| Neurocrine BioSciences, Inc. | 4 | $92 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: INVEGA SUSTENNA, SPRAVATO, ARISTADA, CAPLYTA, REXULTI, Symbravo, Qelbree, Auvelity.
Industry payments across OK — which companies pay providers there.
